Clinical · Molecular biology
Disrupting KRAS-AGO2 interaction: a dual-pronged strategy to sensitize chemo-immunotherapy in KRAS-mutated colorectal cancer
This study investigates the interaction between mutated KRAS and AGO2 in colorectal cancer (CRC), a mechanism that impairs AGO2 function and promotes tumor progression. Researchers developed peptide-gold nanoparticles (Au-pep) to specifically disrupt this interaction, which restored microRNA expression, particularly let-7c-5p. This restoration led to the downregulation of key oncogenic drivers such as KRAS, c-Myc, and Bcl2, suppressing the growth of KRAS-mutated CRC cells and inducing apoptosis. Furthermore, this approach sensitized cells to existing treatments, including 5-fluorouracil and immunotherapy, by regulating ABCC5 and PD-L1.